| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.54B | 3.61B | 3.51B | 3.23B | 1.68B | 1.25B |
| Gross Profit | 2.08B | 2.14B | 1.98B | 1.78B | 1.05B | 767.67M |
| EBITDA | 906.00M | 783.00M | -3.19B | 993.00M | 579.60M | 438.65M |
| Net Income | 455.00M | 513.00M | -3.85B | 394.00M | 341.00M | 286.85M |
Balance Sheet | ||||||
| Total Assets | 16.86B | 17.45B | 16.33B | 20.55B | 19.43B | 2.31B |
| Cash, Cash Equivalents and Short-Term Investments | 921.00M | 1.14B | 861.00M | 578.00M | 630.09M | 973.57M |
| Total Debt | 1.99B | 2.09B | 2.09B | 2.23B | 2.48B | 62.40M |
| Total Liabilities | 3.57B | 3.81B | 3.61B | 3.81B | 4.09B | 288.07M |
| Stockholders Equity | 13.28B | 13.64B | 12.72B | 16.74B | 15.32B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 648.00M | 907.00M | 638.00M | 549.00M | 321.86M | 336.36M |
| Operating Cash Flow | 694.00M | 907.00M | 757.00M | 636.00M | 384.31M | 356.45M |
| Investing Cash Flow | -291.00M | -377.00M | -124.00M | -144.00M | -6.52B | -20.22M |
| Financing Cash Flow | -281.00M | -286.00M | -300.00M | -582.00M | 5.75B | -26.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr4.49B | 29.72 | 18.65% | 1.33% | 3.45% | 4.22% | |
| ― | kr20.47B | 46.40 | 3.34% | 0.73% | -1.29% | ― | |
| ― | kr6.28B | 210.07 | 1.32% | ― | 8.39% | -85.36% | |
| ― | €60.41B | 101.84 | 31.78% | 0.36% | 5.74% | 30.96% | |
| ― | kr60.66B | 29.53 | 6.91% | 2.07% | 6.74% | 21.40% | |
| ― | $1.66B | ― | -15.03% | ― | -21.56% | 70.41% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Vitrolife AB reported a mixed financial performance for Q3 2025, with a 3% growth in sales in local currencies but a 4% decrease in SEK due to currency impacts. The company saw significant growth in the Americas and in its technologies and consumables product groups, despite a challenging currency environment affecting margins. The company also signed a EUR 300 million loan agreement to refinance existing debt and support general corporate purposes, indicating strategic financial management amidst currency challenges.
The most recent analyst rating on (SE:VITR) stock is a Hold with a SEK147.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.